Spero Therapeutics Inc.

(SPRO) Trade

By |

Profile

Spero Therapeutics Inc is a US-based clinical-stage biopharmaceutical company. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections. The company's product candidate, SPR994, is designed as a broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It has developed platform technology known as Potentiator Platform to develop drugs to expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. In addition, the company is developing SPR720, an oral antibiotic designed for the treatment of pulmonary non-tuberculous mycobacterial infections. The pipeline products include SPR741, SPR206, and SPR720.

Contact Information

Website: www.sperotherapeutics.com
Email: IR@sperotherapeutics.com
Main Phone: +1 857 242-1600
Address: 675 Massachusetts Avenue
Address 2: 14th Floor
State: MA
City / Town: Cambridge
Country: US
Postal Code: 02139

Issuer Information

Exchange: NGS
CEO: Ankit Mahadevia
Employees: 57
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

Profile

Spero Therapeutics Inc is a US-based clinical-stage biopharmaceutical company. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections. The company's product candidate, SPR994, is designed as a broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It has developed platform technology known as Potentiator Platform to develop drugs to expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. In addition, the company is developing SPR720, an oral antibiotic designed for the treatment of pulmonary non-tuberculous mycobacterial infections. The pipeline products include SPR741, SPR206, and SPR720.

Contact Information

Website: www.sperotherapeutics.com
Email: IR@sperotherapeutics.com
Main Phone: +1 857 242-1600
Address: 675 Massachusetts Avenue
Address 2: 14th Floor
State: MA
City / Town: Cambridge
Country: US
Postal Code: 02139

Issuer Information

Exchange: NGS
CEO: Ankit Mahadevia
Employees: 57
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

$ 13.26 $ -0.76 (-5.42%)
Last Price 13.26 Change $ -0.76 Change % -5.42 Tick N/A
Bid 13.09 Bid Size 100.00 Ask 14.30 Ask Size 200.00
Open 14.03 High 14.10 Low 13.17 Prev Close 14.02
Last Trade Volume 199,566 52 Wk Hi 14.61 52 Wk Low 5.25
Market Cap 344.4 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 25,970,105.00 EPS (TTM) -4.36 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 0
Number of Buys 0 0
Number of Sells 0 0
Net Activity 0 0
Last 10 Buys Shares
Allen S. Greene 1,000
Allen S. Greene 1,000
Jack Fingerhut 1,000
John J. Gorman 1,000
Allen S. Greene 1,000
Last 10 Sell Shares
N/A 0
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 30 30 30 30
Low Target Price Estimate 16 16 16 16
Mean Target Price Estimate 25.4 25.4 25.4 25.4
Standard Deviation 5.46 5.46 5.46 5.46
Date of Most Recent Estimate 05/23/18 05/23/18 05/22/18 05/23/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 5 5 4 4
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.33 1.33 1.4 1.4